This embedded system project aimed at designing a digital lock using the CodeVisionAVR or Atmel Studio. The system utilizes an AVR microcontroller (ATmega32) to integrate RFID technology for secure ...

LED on the board fades while the application is not connected to the USB port. When connected and the button (SW0) is pressed, the board will print the title "PIC24FJ64GU205 Curiosity Nano Demo" and ...

From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates dominated Europe’s leading cancer conference over the ...

Compare features, performance, and find the right Denon A/V Receiver for your home theater setup. It also never stopped sparring—playfully or otherwise—with its sibling brand Marantz. While Marantz ...

AbbVie’s Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who have received prior lines of treatment. The FDA signed off on AbbVie’s ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

Three common applications where a new class of 8-bit MCUs with advanced analog filtering capabilities support modern systems. As embedded designs have evolved, the 8-bit MCU has evolved from simple ...

Spoiler alert: almond butter isn’t phosphorescent. But powdered milk is, at least to the limit of detection of this homebrew phosphorescence detector. Why spend a bunch of time and money on such a ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate (ADC) after failing to show a favorable benefit-risk profile ...

The 150 wpc Denon AVR-A10H ($4,699) is a scaled-down version of the $6,500 AVR-A1H 8K AV receiver with 13.4 channels instead of 15.4. We explore what features you sacrifice by choosing the AVR-A10H.

Despite some positive trials with new drugs (including immunotherapy) for recurrent cervical cancer, the prognosis for this disease remains poor and additional treatment options are needed. Tisotumab ...

In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody-drug conjugate (ADC) patritumab deruxtecan. The drug, also known as HER3-DXd, was ...